Biosimilar Antibodies

R707 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets CCR7/CD197, a chemokine receptor involved in the regulation of leukocyte migration. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.36 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Etrolizumab, also known as rhuMAb Beta7, is a gut-selective monoclonal antibody that selectively targets the β7 subunit of α4β7 and αEβ7 integrins. This antibody demonstrates high affinity binding, with dissociation constants (Ki) of 18 nM for Human α4β7 and 1.8 nM for Human αEβ7-293 integrins. Etrolizumab is primarily utilized in the research of inflammatory bowel diseases (IBD), making it a valuable tool for studies aimed at understanding and potentially treating these conditions.

ABT-325 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-18 (IL-18). This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain. ABT-325 has a predicted molecular weight of 146.28 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is suitable for a range of immunological applications where IL-18 activity modulation is investigated.

Plonmarlimab (TJ003234) is a monoclonal antibody targeting Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). This antibody is utilized in the investigation of inflammatory conditions such as rheumatoid arthritis, as well as in the study of immune response mechanisms in COVID-19. Plonmarlimab offers a specific tool for researchers exploring the role of GM-CSF in disease pathology and therapeutic intervention.

The Anti-SCN9a/Nav1.7 Antibody is a human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting the SCN9a/Nav1.7 ion channel. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is suitable for use in various biochemical and cellular research applications to study the role of the Nav1.7 channel in pain perception and other neurological functions.

Vonlerolizumab (MOXR 0916) is a humanized IgG monoclonal antibody that functions as an agonist targeting the OX40 receptor. This antibody is specifically designed for the study of cancer immunotherapy, facilitating research into the modulation of T-cell activity and the enhancement of anti-tumor immune responses.

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody designed to selectively target and inhibit the complement C5a receptor 1 (C5aR1). By blocking the interaction between C5aR1 and its ligand C5a, Avdoralimab effectively prevents receptor activation, offering a therapeutic strategy for the study of complement-driven inflammatory diseases and solid tumors. This antibody is pivotal for researchers focusing on the role of the complement system in pathology and the therapeutic potential of complement inhibition.

Plozalizumab (MLN-1202) is a humanized monoclonal antibody that selectively targets the CCR2 (C-C chemokine receptor type 2) receptor. This specificity makes it a valuable tool for investigating the role of CCR2 in malignant melanoma, providing insights that may contribute to the development of targeted therapies for this aggressive cancer.

Tazlestobart is a humanized IgG1κ monoclonal antibody designed to specifically target CTLA4. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Lenzilumab (KB 003) is a humanized monoclonal antibody specifically designed to neutralize colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody is utilized in research focused on COVID-19 and myelomonocytic leukemias, including chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Its targeted action against CSF2/GM-CSF makes it a valuable tool for understanding and potentially modulating inflammatory and immune responses in these disease states.

Rilogrotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets GDF15 (Growth Differentiation Factor 15). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

AMG-119 is a humanized IgG1 monoclonal antibody specifically designed to target delta-like ligand 3 (DLL3). This antibody is particularly useful in research focused on relapsed or refractory small cell lung cancer (SCLC). For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ monoclonal antibody designed to target human cytomegalovirus (hCMV). This antibody exhibits its neutralizing activity by specifically binding to antigenic domain 1 of glycoprotein B, which is located on the envelope of hCMV. Through this targeted interaction, Fiztasovimab effectively inhibits the cell-to-cell transmission of the virus, providing a crucial tool for research into viral pathogenesis and therapeutic intervention strategies.

Verzistobart is a monoclonal antibody of the IgG1κ class, specifically designed to bind to the hepatitis A virus cellular receptor, HAVCR2. This targeted interaction is crucial for research focused on the pathogenesis and therapeutic interventions of hepatitis A, providing a valuable tool for both in vitro and in vivo studies.

Rocatinlimab (AMG 451, KHK4083) is a fully human, non-fucosylated IgG1 monoclonal antibody targeting OX40. This antibody is designed for the investigation of therapeutic pathways in atopic dermatitis (AD) and may be utilized in related immunological research studies.

The Anti-STOP1 Antibody is a human monoclonal antibody derived from Chinese Hamster Ovary (CHO) cells, specifically targeting the STOP1 protein. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the function and regulation of the STOP1 protein.

Vibostolimab is a monoclonal antibody targeting TIGIT (T cell immunoglobulin and ITIM domain), demonstrating significant antitumor activity. This antibody is specifically designed for research involving non-small cell lung cancer (NSCLC) and melanoma, providing a valuable tool for investigations into immune checkpoint pathways and cancer immunotherapy.

Pivekimab is a human IgG1 monoclonal antibody engineered to specifically target interleukin-3 (IL-3) and CD123. This antibody serves as the foundational component in the synthesis of Pivekimab Sunirine, a targeted CD123-directed antibody-drug conjugate (ADC) utilized in therapeutic applications. Pivekimab is primarily employed in research focused on blastic plasmacytoid dendritic cell neoplasm (BPDCN), providing a critical tool for advancing studies in this area of oncology.

Canrivitug is a human IgG1 λ2 monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.

Gevokizumab is a potent monoclonal antibody that targets interleukin-1 beta (IL-1β), employing an allosteric mechanism to modulate IL-1β signaling negatively. This antibody selectively reduces the binding affinity of IL-1β to its signaling receptor, interleukin-1 receptor type I (IL-1RI), rather than affecting the interaction with the IL-1 counter-regulatory decoy receptor, interleukin-1 receptor type II (IL-1RII). This specificity in modulation facilitates the detailed study of IL-1β signaling pathways and their physiological and pathological roles. Gevokizumab is instrumental in research focused on inflammation and immune response, offering potential therapeutic insights into diseases mediated by IL-1β.

ICT-01 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting BTN1A1. This antibody is composed of an IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 146.2 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa.

Tilrekimig is a monoclonal antibody engineered to specifically target human interleukin 4 (IL-4), interleukin 13 (IL-13), and thymic stromal lymphopoietin (TSLP). This antibody is of significant interest for the study of allergic and inflammatory disorders, including asthma and atopic dermatitis. Its specificity for these cytokines makes it a valuable tool in the investigation of the underlying mechanisms of these diseases and the development of targeted therapies.

Coltuximab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD19. This biologic is constructed from human immunoglobulin G1 (huIgG1) heavy chains and human kappa (huκ) light chains, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cusatuzumab (ARGX-110) is a humanized monoclonal antibody targeting CD70. It exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) and effectively blocks the CD70/CD27 signaling pathway. By inhibiting this pathway, cusatuzumab reduces the population of leukemia stem cells (LSCs) and induces gene signatures associated with myeloid differentiation and apoptosis. This antibody is particularly useful in research focused on the pathophysiology and potential therapeutic interventions for leukemia.

Vixarelimab (KPL-716) is a human monoclonal antibody targeting the beta chain of the oncostatin M (OSM) receptor. By binding to this subunit, Vixarelimab effectively inhibits signaling pathways mediated by interleukin-31 (IL-31) and OSM. This antibody is particularly useful in research focused on inflammatory skin conditions, including atopic dermatitis and prurigo nodularis, providing a valuable tool for investigating the molecular mechanisms underlying these diseases and potentially guiding therapeutic interventions.

Lintuzumab (HUM-195) is a humanized monoclonal antibody targeting CD33, designed to modulate immune responses in acute myeloid leukemia (AML). By reducing the production of TNFα-induced pro-inflammatory cytokines and chemokines, Lintuzumab effectively suppresses inflammatory pathways in AML cells. It facilitates tumor cell eradication via mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), demonstrating efficacy against both multidrug-resistant (MDR) and non-resistant AML cell lines, as well as primary samples from AML patients. In vivo studies have shown that Lintuzumab significantly enhances survival rates and diminishes tumor burden in murine models, highlighting its potential as a therapeutic agent in oncology research.

The Anti-TNFRSF7/CD27 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets TNFRSF7/CD27, a critical receptor involved in the regulation of T and B cell function. This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, exhibiting a molecular weight of approximately 145 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. This product is essential for research focusing on immune response modulation and the study of diseases characterized by altered TNFRSF7/CD27 activity.

Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-3 receptor alpha, also known as CD123. This antibody has a molecular weight of approximately 146.14 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This antibody is designed for precise targeting, making it suitable for a range of research applications focusing on the biology and pathophysiology of IL-3Ra/CD123.

LGN-523 (AML-01) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD98. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, featuring a predicted molecular weight of 145.66 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. LGN-523 (AML-01) is suitable for a variety of research applications focusing on the role of CD98 in cellular processes.

DFRF4539A (RG-7598) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets FcRH5/IRTA2/CD307e, a protein expressed on the surface of certain immune cells. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a molecular weight of approximately 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

CTX-2026 is a fully human monoclonal antibody that specifically targets CD277, a protein implicated in the immunological landscape of tumors. This antibody has demonstrated a potent anti-tumor effect in ovarian cancer models, suggesting its utility in oncological research focused on the modulation of tumor microenvironments. CTX-2026 is ideal for investigations into cancer biology, particularly for studies aiming to elucidate the role of CD277 in tumor immunology and therapeutic intervention.

The Anti-Fy3 Antibody (MIMA-29) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target the human Fy3 antigen. For optimal experimental control, it is recommended to use Mouse IgG2a kappa Isotype Control alongside this antibody to accurately assess antibody specificity and ensure accurate data interpretation.

Imsidolimab (ANB 019) is a high-affinity humanized monoclonal antibody that targets IL-36 receptor (IL-36R), effectively antagonizing IL-36 cytokine signal transduction. This antibody is designed for potential therapeutic use in managing generalized pustular psoriasis (GPP) and various other inflammatory skin conditions. Its specificity for IL-36R makes it a valuable tool for research and treatment development in dermatological inflammation.

Peluntamig is a bispecific antibody of the H-γ1_L-κ type that targets both CD47 and DLL3. This dual specificity allows for enhanced therapeutic potential in oncology research, leveraging the roles of CD47 in "don't eat me" signal inhibition and DLL3 in cancer stem cell signaling pathways.

Tiragolumab functions as an immune checkpoint inhibitor by targeting the T-cell immunoglobulin and ITIM domain (TIGIT). This monoclonal antibody can be utilized either as a monotherapy or in conjunction with Atezolizumab, a PD-L1 inhibitor, to potentially enhance therapeutic efficacy against a variety of solid tumors, with a notable application in the treatment of non-small cell lung cancer (NSCLC). This dual approach may offer a strategic advantage in the modulation of immune responses in oncology settings.

Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.

The Anti-PACAP38 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the peptide PACAP38. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, the Human IgG4 kappa Isotype Control is recommended. This antibody is designed for the precise identification and study of PACAP38's role and function in biological systems.

Venanprubart is a human IgG4 κ monoclonal antibody targeting BTLA (B and T Lymphocyte Attenuator). For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the specific detection and study of BTLA's role in immune regulation, making it an essential tool for immunology research.

NI-0701 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL5/RANTES. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG2 kappa, Isotype Control. NI-0701 is applicable in research focused on the biological roles and therapeutic targeting of the chemokine CCL5/RANTES.

Podentamig is a chimeric antibody designed to target CD3E and TNFRSF17. It features a unique VH-VH'-(scFv-heavy -λ) configuration, enhancing its specificity and binding affinity for these antigens. This antibody is engineered for advanced research applications, focusing on the modulation of immune responses and the study of B-cell malignancies.

Timcevibart is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Ibalizumab (TMB-355) is a humanized IgG4 monoclonal antibody designed to inhibit HIV-1 entry into cells by specifically binding to the CD4 receptor. This targeted mechanism makes Ibalizumab a valuable tool for research into the prevention and treatment of HIV-1 infection.

Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody specifically designed to target interleukin-21. This therapeutic protein is engineered to bind selectively to interleukin-21, a cytokine implicated in the pathogenesis of various autoimmune diseases, thereby modulating immune responses and providing potential therapeutic benefits in disorders characterized by excessive or aberrant cytokine activity.

Oloctinebart is a humanized IgG4-kappa monoclonal antibody targeting LGALS3. This antibody is specifically designed to inhibit the formation of amyloid beta oligomers, which are implicated in the pathogenesis of Alzheimer's disease and other amyloid-related disorders. Oloctinebart's targeted action makes it a valuable tool for research focused on the molecular mechanisms of amyloidosis and potential therapeutic interventions.

Gatralimab (GZ-402668) is an IgG1 monoclonal antibody specifically designed to target CD52. This antibody is utilized in various research studies to investigate its potential therapeutic applications and mechanism of action in modulating immune responses.